TVT Remains Superior for Long-Term Satisfaction in SUI, but PAHG Offers a Safer Profile: Insights from a 5-Year Randomized Trial

Introduction: The Evolution of Stress Urinary Incontinence Management

Stress urinary incontinence (SUI) remains a significant global health concern, affecting millions of women and profoundly impacting their quality of life, physical activity, and psychological well-being. For over two decades, the tension-free vaginal tape (TVT) has been regarded as the gold standard for the surgical treatment of female SUI due to its high success rates and long-term durability. However, the medical community and regulatory bodies have recently faced intense scrutiny regarding the safety of mesh-based implants. Complications such as mesh erosion, chronic pain, and dyspareunia have led to a demand for effective, minimally invasive, and mesh-free alternatives.

One such alternative is the transurethral injection of polyacrylamide hydrogel (PAHG), a non-resorbable bulking agent. While initial results for PAHG were promising, the clinical community has lacked robust, long-term comparative data to determine if this less invasive procedure can truly compete with the efficacy of TVT. The publication of the 5-year follow-up data from the Helsinki University Hospital trial in NEJM Evidence provides critical clarity for clinicians and patients navigating these choices.

Study Design and Methodology

The Helsinki University Hospital study was a randomized, controlled, noninferiority trial designed to compare the long-term outcomes of TVT and PAHG. The trial initially enrolled 223 women with primary SUI, randomized to receive either the gold-standard TVT or PAHG (specifically Bulkamid).

The primary outcome was patient satisfaction, measured using a Visual Analog Scale (VAS) ranging from 0 to 100, where a score of 80 or higher was predefined as a successful outcome. The noninferiority margin was set at 20 percentage points. Secondary outcomes included objective cure rates (evaluated by the cough stress test), the need for repeat interventions, and long-term complication rates. The 5-year follow-up included 195 women, representing an impressive 92% of the original cohort, providing high statistical power for the results.

Five-Year Results: Satisfaction and Efficacy

At the 5-year mark, the data revealed a clear distinction between the two interventions. In the TVT group, the median satisfaction score was 98 (Interquartile Range [IQR], 86 to 100). In contrast, the PAHG group reported a median satisfaction score of 90 (IQR, 75 to 99). While both groups reported high median satisfaction, the proportion of women reaching the success threshold (VAS ≥ 80) was significantly different.

In the TVT group, 92.7% of participants reached the satisfaction threshold, compared to 74.7% in the PAHG group. The difference of 18.0 percentage points (95% CI, 7.7 to 28.0) meant that PAHG failed to meet the noninferiority criteria. This suggests that while PAHG is effective for many, it does not provide the same level of long-term subjective success as the mid-urethral sling.

These findings are consistent with the 3-year follow-up data, where TVT also outperformed PAHG in satisfaction (94.6% vs 67.7%). Interestingly, the PAHG satisfaction rates improved slightly between years 3 and 5, which may be attributed to the crossover of patients who were unsatisfied with PAHG and subsequently received TVT, though the analysis primary focused on outcomes before crossover.

Objective Cure and Durability

Objective efficacy measures further supported the superiority of TVT. In the 3-year data, the cough stress test—a rigorous objective measure of continence—was negative in 95.7% of the TVT group compared to 78.1% of the PAHG group. By year five, the trend remained stable, reinforcing the concept that the mechanical support provided by a mid-urethral sling is inherently more robust than the mucosal coaptation provided by a bulking agent.

Safety Profile: The Advantage of PAHG

While TVT led in efficacy, the study highlighted the trade-off regarding safety. Complications were significantly more frequent in the TVT group. Over the 5-year period, 43.8% of women in the TVT group experienced a peri- or postoperative complication, compared to only 22.2% in the PAHG group.

Common complications in the TVT group included bladder perforation during surgery, voiding dysfunction, and mesh-related issues. While most complications in the TVT group were managed successfully, the sheer frequency of events highlights why many patients are hesitant to undergo mesh-based procedures. PAHG, being a minimally invasive injection, offered a much smoother recovery profile and fewer long-term adverse events, making it an attractive option for patients prioritizing safety or those with contraindications to more invasive surgery.

Expert Commentary: Balancing Efficacy and Safety

Clinicians must interpret these results within the context of shared decision-making. The 5-year data confirms that TVT remains the most effective treatment for SUI in terms of both subjective satisfaction and objective cure. For a patient whose primary goal is the highest possible chance of complete dryness, TVT remains the recommended first-line surgical option.

However, the PAHG results should not be viewed as a failure. A 74.7% satisfaction rate at five years for a minimally invasive, non-mesh procedure is substantial. For many women—particularly those who are older, those who wish to avoid mesh, or those with comorbidities that increase surgical risk—PAHG represents a viable and durable alternative. The lower complication rate is a powerful selling point that may outweigh the slightly lower efficacy for a significant subset of the population.

Furthermore, PAHG does not preclude future surgery. Patients who do not achieve satisfactory results with bulking agents can still proceed to a TVT, whereas managing complications from a failed TVT can be significantly more complex.

Conclusion

The 5-year results of this landmark trial provide the long-term evidence needed to counsel patients accurately. PAHG is not noninferior to TVT; it is objectively and subjectively less effective at the 5-year mark. However, it is also twice as safe in terms of complication rates. These findings reinforce the gold-standard status of TVT while simultaneously validating PAHG as a safe, durable, and effective secondary option for women who prefer a minimally invasive approach.

Funding and ClinicalTrials.gov

This study was funded by Helsinki University Hospital and Contura. The trial is registered at ClinicalTrials.gov under the identifier NCT02538991.